Press Release

Spinal Muscular Atrophy (SMA) Treatment Market Set to Expand from USD 2.3 Billion in 2023 to USD 30.2 Billion by 2030

The Global Spinal Muscular Atrophy (SMA) Treatment Market size was valued at around USD 2.3 billion in 2023 and is projected to reach around USD 30.2 billion by 2030. Along with this, the market is anticipated to grow at a CAGR of around 18.2% during the forecast period, i.e., 2025-30, cites MarkNtel Advisors in the recent research report. This growth in the market is primarily driven by the advancement in treatment and medications for spinal muscular atrophy.  Furthermore, the innovation driven by the growing focus on the research and development of rare genetic disorders is also adding to the market growth. The increasing awareness about SMAs due to the rise in the identification and early detection of SMAs during the infancy of the child is leading to the growing demand for the market worldwide.

Since the SMA treatment involves significant expense that can translate to millions of dollars. For example, Zolgensma which is a gene therapy medication for Spinal Muscular Atrophy cost about USD 2.1 million during its single use. Another SMA medication called Spinraza which is administered four times a year throughout life costs around USD 350,000 for a single dosage. In such a scenario, the increasing need for government funding/subsidy and participation of healthcare organizations become crucially important.

Apart from this, the introduction of advanced technologies, including gene replacement therapies and antisense oligonucleotide (ASO) treatments, along with the addition of the increasing pipeline of drugs is fueling market growth, further states the research report, Global Spinal Muscular Atrophy (SMA) Treatment Market Analysis, 2025.”

Global Spinal Muscular Atrophy (SMA) Treatment Market Segmentation Analysis

Gene Therapy Holds the Largest Market Share

Based on the treatment, the market is further bifurcated into gene therapy and disease-modifying drugs. Gene therapy is the leading category that holds over 70% market share in the Global Spinal Muscular Atrophy Treatment Market in 2024. Gene therapy offers a long-lasting solution to SMA patients that improves their conditions. This is because the medication primarily targets the gene that is responsible for the condition. This is the main reason for its dominance in the global market of SMA treatment.  For example, nusinersen (Spinraza) which has been approved by the Food and Drug Administration (FDA) is a medication for SMA treatment. It works by targeting the specific gene responsible for the SMA condition of the patient. There it helps in increasing the production of sensor motor neuron (SMN) protein whose deficiency has caused the SMA.

North America Leads the SMA Treatment Industry

In the Global Spinal Muscular Atrophy Market, North America holds a market share of more than 40%. The primary reason for this due to presence of the United States of America (USA) in the region. The country's presence fuels market growth because of the existence of advanced medical research and development facilities, technology, and infrastructure. This provides critical diagnosing and treatment capabilities for SMA in the country by developing and deploying innovative therapies and medications for SMA patients.

Furthermore, the presence of such extensive infrastructure and capabilities attracts SMA patients to seek treatment in the country. Apart from this, the early screening and detection programs to identify SMA patients during their infancy for further treatment also drive the market. These scenarios indicate that a healthy growth of the market in the region will also lead to the market’s growth worldwide.

Competitive Landscape

With strategic initiatives, such as mergers, collaborations, and acquisitions, the leading market companies, including Biogen, Novartis AG, F. Hoffmann-La Roche Ltd, Cytokinetics, PTC Therapeutics, Inc, Ionis Pharmaceuticals Inc., Astellas Pharma Inc., NMD Pharma A/S, Genzyme Corporation, Genentech, Inc., Pfizer Inc., Scholar Rock Holding Corporation, Novo Nordisk A/S, Takeda Pharmaceutical Co. Ltd, and others are looking forward to strengthening their market positions.

Key Questions Answered in the Research Report

1. What are the industry’s overall statistics or estimates (Overview, Size- By Value, Forecast Numbers, Segmentation, Shares)?
2. What are the trends influencing the current scenario of the market?
3. What key factors would propel and impede the industry across the globe?
4. How has the industry been evolving in terms of geography and product adoption?
5. How has the competition been shaping up across various regions?
6. How have buying behavior, customer inclination, and expectations from product manufacturers been evolving during 2020-30?
7. Who are the key competitors, and what strategic partnerships or ventures are they coming up with to stay afloat during the projected time frame?